Expertise in
7
conditions

Tommaso M. De Pas

Cliniche Humanitas Gavazzeni
Bergamo, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Cliniche Humanitas Gavazzeni
Bergamo, IT 

Overview

Tommaso De Pas practices practicing medicine in Bergamo, Italy.

Mr. De Pas is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Thymic Epithelial Tumor, Adult Soft Tissue Sarcoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.

He is actively involved in clinical research, co-authoring 141 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Cliniche Humanitas Gavazzeni
Bergamo, 24125, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Epithelioid Sarcoma. An Observational Study
Epithelioid Sarcoma. An Observational Study
Enrollment Status: Recruiting
Publish Date: November 18, 2025
Intervention Type: Other
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Olaparib
Study Phase: Phase 2
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Enrollment Status: Completed
Publish Date: February 01, 2024
Intervention Type: Other
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 2
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Withdrawn
Publish Date: May 13, 2019
Intervention Type: Drug
Study Phase: Phase 3
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)
Enrollment Status: Completed
Publish Date: May 10, 2019
Intervention Type: Drug
View 6 Less Clinical Trials

141 Total Publications

"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 15, 2026

Frequently Asked Questions about Tommaso M. De Pas

Is Tommaso M. De Pas a top-rated expert for Thymic Epithelial Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Tommaso M. De Pas is classified as an Distinguished expert for Thymic Epithelial Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tommaso M. De Pas participate in research or clinical trials?

Yes. Tommaso M. De Pas has published 141 articles and abstracts on conditions like Thymic Epithelial Tumor. You can view a list of Tommaso M. De Pas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. De Pas's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile